COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04471064
Recruitment Status : Not yet recruiting
First Posted : July 14, 2020
Last Update Posted : July 14, 2020
Proswell Medical Corporation
Information provided by (Responsible Party):
Shijiazhuang Yiling Pharmaceutical Co. Ltd

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : December 2022